Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 Genitourinary Cancers Symposium /
Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma

26th - 28th Feb 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.02.15
Views: 2730
Rating:

Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA

Dr Voss talks to ecancertv at ASCO GU 2015 on part 1 of the DART Study, a phase II randomised trial using dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma. Results have shown that the combination of dalantercept and axitinib is well tolerated and demonstrated and associated with encouraging activity in patients with prior VEGF, mTOR, and immune therapies. 

For more information on the DART Study, please click here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation